Business
Posting of Circular and Notice of General Meeting
Posting of Circular and Notice of General Meeting.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n\n \n \n4 April 2025\nN4 Pharma plc\n \n(\"N4 Pharma\" or the \"Company\")\n \nPosting of Circular and Notice of General Meeting\n \nN4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, announces that it is today posting a circular containing a Notice of General Meeting and Forms of Proxy to shareholders regarding the proposed Placing and Subscription, as announced on 1 April 2025, and the resolutions to be put to shareholders at the General Meeting. \n \nThe General Meeting will be held on 22 April 2025 at 11 a.m. at the offices of Shakespeare Martineau LLP, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR.\n \nThe circular and Notice of General Meeting will shortly be available on the Company's website: https://www.n4pharma.com/investors/investor-information/\n \n- Ends -\n \nFor more information please contact:\n \n\n\n\n\nN4 Pharma plc\nNigel Theobald, CEO\nLuke Cairns, Executive Director\n \nEngage with us directly at N4 Pharma Investor Hub\n \nTo find out more, visit\n\n\n \nVia N4 Pharma Investor Hub\n \n \nSign up at investors.n4pharma.com\n \nhttps://investors.n4pharma.com/link/weY9Ye\n\n\n\n\nSP Angel Corporate Finance LLP\nNominated Adviser and Joint Broker\nMatthew Johnson/Jen Clarke (Corporate Finance)\nVadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)\n\n\nTel: +44 (0)20 3470 0470\n\n\n\n\nTurner Pope Investments (TPI) Limited\nJoint Broker\nAndy Thacker\nJames Pope\n\n\nTel: +44 (0)20 3657 0050\n\n\n\n\nNorthstar Communications Limited\nInvestor Relations\nSarah Hollins\n\n\nTel: +44 (0)113 730 3896\n \n\n\n\n\n \nAbout N4 Pharma\nN4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.\n \nRNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.\n \nN4 Pharma i...